Evidence map›Paper›PMID 41272348›Full record

ArticlePediatric nephrology (Berlin, Germany)2026

High adherence to angiotensin-converting enzyme inhibitor in children and adolescents with Alport syndrome: objective verification using liquid chromatography-mass spectrometry.

Jan Boeckhaus, Burkhard Tönshoff, Lutz T Weber, Dieter Haffner, Lars Pape, Kay Latta, Henry Fehrenbach, Baerbel Lange-Sperandio, Matthias Kettwig, Sabine König and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jan BoeckhausClinic for Nephrology and Rheumatology, University Medical Center Göttingen, Goettingen, Germany. jan.boeckhaus@med.uni-goettingen.de.ORCID http://orcid.org/0009-0006-2021-9255
Burkhard TönshoffDepartment of Pediatrics I, University Children's Hospital Heidelberg, Heidelberg, Germany.
Lutz T WeberPediatric Nephrology, Children's and Adolescents' Hospital, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Dieter HaffnerDepartment of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Hannover, Germany.
Lars PapeDepartment of Pediatrics II, University Children's Hospital, University of Duisburg-Essen, Essen, Germany.
Kay LattaClementine Kinderhospital Frankfurt, Frankfurt, Germany.
Henry FehrenbachPediatric Nephrology, Children's Hospital, Memmingen, Germany.
Baerbel Lange-SperandioDr. V. Hauner Children's Hospital, Ludwig Maximilians University, Munich, Germany.
Matthias KettwigDepartment of Pediatrics and Adolescent Medicine, University Medical Center Göttingen, Göttingen, Germany.
Sabine KönigUniversity Children's Hospital Münster, Münster, Germany.
Ulrike John-KroegelDivision of Pediatric Nephrology, University Children's Hospital, Jena, Germany.
Jutta GellermannPediatric Nephrology, Charité Children's Hospital, Berlin, Germany.
Matthias GalianoDepartment of Pediatrics and Adolescent Medicine, University Hospital, Friedrich-Alexander-University Erlangen, Erlangen, Germany.
Angelika HafkeDepartment of Clinical Chemistry, University Medical Center Göttingen, Göttingen, Germany.
Frank StreitDepartment of Clinical Chemistry, University Medical Center Göttingen, Göttingen, Germany.
Oliver GrossClinic for Nephrology and Rheumatology, University Medical Center Göttingen, Goettingen, Germany.

Funding

Bundesministerium für Bildung und Forschung 01KG1104
6 · The paper itself

Abstract

backgroundKidney failure (KF) in children and adolescents leads to reduced lifespan and compromised health. Alport syndrome (AS) is a leading hereditary cause of KF in children. Angiotensin-converting enzyme inhibitors (ACEi) have demonstrated efficacy in delaying KF in young people living with AS, but non-adherence can compromise their therapeutic benefits. To investigate the adherence to ACEi in children and adolescents with AS, a liquid chromatography-mass spectrometry (LCMS)-based method was developed for objective verification of recent medication intake at two different time points in this cohort study.

methodsUrine samples from 58 children enrolled in the EARLY PRO-TECT Alport trial were analyzed. An LCMS-based method was established and validated to simultaneously screen and quantify both ramipril and ramiprilat in urine samples. Participants were not informed in advance of the medication intake measurements.

resultsA total of 106 urine samples from 58 patients with early stages of chronic kidney disease (mean estimated glomerular filtration rate, 130 ± 32 mL/min/1.73 m

conclusionThis study demonstrated that children with chronic kidney disease, when treated with ACEi within a clinical trial, show high adherence to the prescribed medication.

Indexed as

Angiotensin-Converting Enzyme InhibitorsMedication AdherenceNephritis, HereditaryRamiprilAdolescentChildChild, PreschoolChromatography, LiquidFemaleGlomerular Filtration RateHumansLiquid Chromatography-Mass SpectrometryMaleMass SpectrometryAngiotensin-Converting Enzyme InhibitorsRamiprilAdherenceAlport syndromeClinical trialHereditary kidney diseaseRamipril

Identifiers

PMID41272348
PMCPMC12953493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.